| Trial ID: | L0187 |
| Source ID: | NCT03778567
|
| Associated Drug: |
Telbivudine
|
| Title: |
Renoprotective Effects of Telbivudine in Chronic Hepatitis B
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Hepatitis B, Chronic|Chronic Kidney Diseases
|
| Interventions: |
DRUG: Telbivudine
|
| Outcome Measures: |
Primary: Renal function change, Describe the change in renal function after 108 weeks of telbivudine switch, 108 weeks | Secondary: Virologic suppression, Rate of virologic suppression, 108 weeks|Adverse events, Rate of adverse events, 108 weeks
|
| Sponsor/Collaborators: |
Sponsor: The University of Hong Kong
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
31
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: |Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2013-08-01
|
| Completion Date: |
2018-05-31
|
| Results First Posted: |
|
| Last Update Posted: |
2018-12-19
|
| Locations: |
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
|
| URL: |
https://clinicaltrials.gov/show/NCT03778567
|
